Increasing Influenza and Tdap Vaccination of Pregnant Women
The VAX-MOM Study: Increasing Influenza and Tdap Vaccination of Pregnant Women
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center (URMC)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients
- Sex is female
- Pregnant
- identified as being eligible for influenza or Tdap vaccine
Providers
- any provider, nurse or staff associated with the participating sites
Exclusion Criteria:
Patients
- none
Providers
- none
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard of Care
|
Standard vaccine education and processes provided to patients by obstetric practices.
|
|
Experimental: VAX-MOM Intervention
|
The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of Influenza Vaccination
Time Frame: 10/1/2021-6/30/2022 (intervention flu season)
|
Influenza vaccination rate during pregnancy.
Vaccination status will be obtained from patient electronic health records.
|
10/1/2021-6/30/2022 (intervention flu season)
|
|
Rate of Tdap Vaccination
Time Frame: 7/1/2021 - 6/30/2022 (intervention period)
|
Tdap vaccination rate during pregnancy.
Vaccination status will be obtained from patient electronic health records.
|
7/1/2021 - 6/30/2022 (intervention period)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients seen in the practices
Time Frame: 12 months during intervention period
|
12 months during intervention period
|
|
Number of providers/nurses/staff completing training modules
Time Frame: 12 months during intervention period
|
12 months during intervention period
|
|
Flu and Tdap vaccination rates by insurance group (public vs private)
Time Frame: 12 months during intervention period
|
12 months during intervention period
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY00005115
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.